PENTIXAPHARM
PentixaPharm GmbH, a joint venture of Scintomics GmbH and 1717 Life Science Ventures GmbH, is committed to develop PentixaFor and PentixaTher as a theranostic radiopharmaceutical pair, specifically targeting the CXCR4-receptor expressed in most fast progressing diseases, particularly malignant cancers. Funding is dedicated for a phase II trial of the imaging compound PentixaFor and for a phase I trial of the therapeutic compound PentixaTher in Central Nervous System (CNS) Lymphoma while supporting proof-of-concept studies in various other indications.
PENTIXAPHARM
Industry:
Biotechnology Health Care Life Science Pharmaceutical
Founded:
2019-01-01
Address:
Würzburg, Bayern, Germany
Country:
Germany
Website Url:
http://www.pentixapharm.com
Total Employee:
1+
Status:
Active
Total Funding:
15 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Content Delivery Network JsDelivr Dynatrace
Similar Organizations
Frontier Biotechnologies
Frontier Biotechnologies is a commercial-stage bio-pharmaceutical company.
Menten AI
Menten AI develops peptide and protein therapeutics using machine learning and quantum computing.
Current Employees Featured
Founder
Investors List
Eckert Life Science Accelerator
Eckert Life Science Accelerator investment in Series A - Pentixapharm
Official Site Inspections
http://www.pentixapharm.com Semrush global rank: 5.2 M Semrush visits lastest month: 1.56 K
- Host name: 198.49.23.144
- IP address: 198.49.23.144
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Pentixapharm" on Search Engine
Pentixapharm
Empfohlen. Pentixapharm is a radiopharmaceutical development company founded in 2019, with its headquarters in Würzburg, Germany. It is committed to develop the innovative theranostic pair PentixaFor and PentixaTher, two small peptide-based radiopharmaceuticals that specifically target the CXCR4-receptor.See details»
About Us — Pentixapharm
About Us. Pentixapharm is a radiopharmaceutical development company founded in 2019, with its headquarters in Würzburg, Germany. It is committed to develop the innovative theranostic pair PentixaFor and PentixaTher, two small peptide-based radiopharmaceuticals that specifically target the CXCR4-receptor expressed in hematological and solid ...See details»
Pentixapharm - Crunchbase Company Profile & Funding
Headquarters Regions European Union (EU), Europe, Middle East, and Africa (EMEA) Founded Date 2019. Founders Hakim Bouterfa. Operating Status Active. Last Funding Type Series A. Legal Name Pentixapharm GmbH. Company Type For Profit. PentixaPharm GmbH, a joint venture of Scintomics GmbH and 1717 Life Science Ventures GmbH, is …See details»
Pipeline — Pentixapharm
Pipeline. Our clinical pipeline consists of two compounds, PentixaFor and PentixaTher. PentixaFor is a small peptide-based Gallium-68 PET imaging agent that uniquely targets the C-X-C receptor, which is overexpressed on a variety of malignant diseases. This compound is deployed in two major programs, addressing distinct indications in Oncology ...See details»
PENTIXAPHARM receives confirmation from EMA that its Lead …
Feb 10, 2021 Würzburg (Germany), February 10th, 2021 – PentixaPharm, a radiopharmaceutical development company, received confirmation from the European Medicines Agency (EMA) last week that its lead candidate PentixaFor may be advanced directly in a phase III development program.See details»
News — Pentixapharm
Jun 8, 2023 PentixaPharm, founded in 2019, is a radiopharmaceutical development company committed to developing the innovative theranostic pair PentixaFor and PentixaTher. PentixaFor and PentixaTher are two-small peptide-based radiopharmaceuticals, which specifically target the CXCR4-receptor.See details»
Eckert & Ziegler Strahlen- und Medizintechnik AG Acquires Direct ...
Apr 19. Major Change in Shareholding Structure. Würzburg (Germany), April 19th, 2021 – Eckert & Ziegler Strahlen- und Medizintechnik AG has acquired several share packages from the founders of PentixaPharm GmbH.See details»
Eckert & Ziegler Bebig SA acquires Pentixapharm - Crunchbase
Apr 16, 2021 Summary. Overview. Acquired Organization: Pentixapharm Pentixapharm develop PentixaFor and PentixaTher as a theranostic radiopharmaceutical pair. Acquiring Organization: Eckert & Ziegler Bebig SA Eckert & Ziegler BEBIG SA is a company involved in the active implantable medical devices segment of the health care sector. Announced …See details»
First CNS Lymphoma Patient Dosed in Phase I/II PTT101 Study …
Nov 22. Berlin/Würzburg, 22 November 2023, Pentixapharm AG, a developer of innovative radiopharmaceuticals owned by Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) today has announced that a first patient has been treated in a dose-finding clinical phase I/II study with Yttrium (90Y) anditixafortide (PentixaTher) at the ...See details»
Eckert & Ziegler Partners with UHN and CanProbe to Advance …
Eckert & Ziegler and its subsidiary, PentixaPharm GmbH, are working with CanProbe and UHN to provide PENTIXAFOR to patients in Toronto. The intent is to provide further support toward the approval of PENTIXAFOR as a diagnostic agent for a …See details»
PENTIXAPHARM Secures € 15 Million Series A Financing
Feb 6, 2020 PentixaPharm GmbH, a joint venture of Scintomics GmbH and 1717 Life Science Ventures GmbH, is committed to develop PentixaFor and PentixaTher as a theranostic radiopharmaceutical pair, specifically targeting the CXCR4-receptor expressed in most fast progressing diseases, particularly malignant cancers.See details»
Pentixapharm | VentureRadar
Pentixapharm | VentureRadar. Location: Germany. Privately Held. Develops innovative theranostic radiopharmaceuticals, PentixaFor and PentixaTher, targeting CXCR4-receptors in fast-progressing diseases, including hematological, …See details»
Scintomics and 1717 Life Science Ventures Team up | News · …
May 15, 2019 PentixaPharm GmbH, based in Würzburg, is committed to develop PentixaFor and PentixaTher as a theranostic radiopharmaceutical pair, specifically targeting the CXCR4-receptor expressed in most fast progressing diseases, particularly malignant cancers.See details»
PentixaTher by PentixaPharm for Secondary CNS Lymphoma: …
Premium Insights. February 16, 2024. PentixaTher by PentixaPharm for Secondary CNS Lymphoma: Likelihood of Approval. Brought to you by. PentixaPharm. PentixaTher. Share this article. PentixaTher is under clinical development by PentixaPharm and currently in Phase II for Secondary CNS Lymphoma.See details»
PentixaTher by PentixaPharm for Primary CNS Lymphoma: …
Premium Insights. April 1, 2024. PentixaTher by PentixaPharm for Primary CNS Lymphoma: Likelihood of Approval. Brought to you by. PentixaPharm. PentixaTher is under clinical development by PentixaPharm and currently in …See details»
Pentixapharm - Funding, Financials, Valuation & Investors
Pentixapharm is funded by Eckert Life Science Accelerator. Unlock for free. Funding Rounds. Number of Funding Rounds 1. Total Funding Amount. Unlock for free. Pentixapharm has raised a total of. €15M. in funding over 1 round. This was a Series A round raised on Feb 6, 2020. Which funding types raised the most money? Show.See details»
Haematology and secondary hypertension: pioneering …
PentixaPharm AG, based in Würzburg and Berlin, was founded in 2019 as a medical start-up and, since June 2022 and with a workfwwwldWüddgssssGslassaorce of over 25 people, has been part of Eckert und Strahlen- und Medizintechnik AG.See details»
[90Y]Y-PentixaTher - PentixaPharm - AdisInsight
Drug Profile. [90Y]Y-PentixaTher - PentixaPharm. Alternative Names: [90Y]Y PentixaTher; [90Y]Y-PTT; Yttrium (90Y)anditixafortide. Latest Information Update: 12 Jan 2024. Price : $50 * Buy Profile. Adis is an information provider. We do …See details»
68Ga PentixaFor/90Y PentixaTher - PentixaPharm - AdisInsight
Contact your organization’s admin about adding this content to your AdisInsight subscription. Buy a PDF version of the profile. Request a free trial. A theranostic radiopharmaceutical pair of 68Ga PentixaFor and 90Y PentixaTher labelled with ß-emitters, targeting CXCR4-receptor is being developed by.See details»
Pentixapharm - Crunchbase
Pentixapharm develop PentixaFor and PentixaTher as a theranostic radiopharmaceutical pair.See details»